XNCR
Xencor IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$914.17M
P/E Ratio
—
EPS
$-2.29
Beta
0.93
52W High
$18.69
52W Low
$6.92
50-Day MA
$12.16
200-Day MA
$12.78
Dividend Yield
—
Profit Margin
-177.10%
Forward P/E
68.03
PEG Ratio
0.00
About Xencor Inc
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed to treat cancer patients and autoimmune diseases in the United States and internationally. The company is headquartered in Monrovia, California.
Fundamentals
| Revenue (TTM) | $97.36M |
| Gross Profit (TTM) | $-148.16M |
| EBITDA | $-201.80M |
| Operating Margin | -1724.00% |
| Return on Equity | -29.80% |
| Return on Assets | -16.20% |
| Revenue/Share (TTM) | $1.30 |
| Book Value | $8.84 |
| Price-to-Book | 1.77 |
| Price-to-Sales (TTM) | 9.39 |
| EV/Revenue | 6.62 |
| EV/EBITDA | -17.27 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -86.20% |
| Shares Outstanding | $74.14M |
| Float | $54.48M |
| % Insiders | 1.18% |
| % Institutions | 115.47% |
Historical Volatility
HV 10-Day
51.24%
HV 20-Day
57.56%
HV 30-Day
59.42%
HV 60-Day
56.26%
HV Rank
32.9%
Volatility is currently contracting
Analyst Ratings
Consensus ($28.50 target)
3
Strong Buy9
Buy2
HoldMore HEALTHCARE Stocks
Data last updated: 6/13/2026